SEC Filing Summary: Xenomics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenomics, Inc. on April 20, 2006, covering events occurring on April 18, 2006. The registrant is incorporated in Florida with principal executive offices in New York, New York. Note: The request metadata referenced "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance action regarding equity compensation.
Material Changes
On April 18, 2006, the Board of Directors amended the stock option agreement for Christoph Bruening, a former director. The material changes include:
- Immediate vesting of an additional 20,000 stock options.
- These options are in addition to 20,000 options that were already vested.
- The exercise period for the vested options was extended to ten (10) years from the original grant date of January 16, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to disclose the entry into a material definitive agreement regarding the amended stock option plan.
Investor Verification Checklist
- Verify the total number of outstanding options held by Christoph Bruening post-amendment.
- Confirm the impact of the immediate vesting on the company's share count and potential dilution.
- Review the attached Exhibit 10.1 for specific terms regarding the extended exercise period.
- Check subsequent filings for any financial impact related to the accelerated vesting.